For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Decision:
- None selected
- Process:
- TA
- ID number:
- 2706
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 June 2026 | Awaiting development. to be suspended |
| 29 June 2026 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 09 January 2024 | Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual